The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective

William L. Dahut, MD, received his MD from Georgetown University in Washington, DC. He completed clinical training in internal medicine at the National Naval Medical Center in Bethesda, Maryland, followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of the National Cancer Institute (NCI). Dr. Dahut worked as an attending physician in the NCI-Navy Medical Oncology Branch until 1995. He then joined the faculty of the Georgetown Lombardi Comprehensive Cancer Center before returning to NCI in 1998. Dr. Dahut’s primary research interest has been in the development of novel therapeutic strategies for the treatment of adenocarcinoma of the prostate. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy, and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment are active and demonstrate the ability to maintain a robust immunologic response.

In 2009, Dr. Dahut was appointed as CCR Clinical Director. In this capacity, he oversees and assures the quality of medical care delivered to patients participating in CCR clinical trials. In 2012, Dr. Dahut was appointed as a CCR Deputy Director, and then in 2016 was selected to become the CCR Scientific Director for Clinical Research.